Hoya Vision Care’s MiYOSMART iQ Lenses Show No Myopia Progression on Average at Six Months, Clinical Trial Shows

HONG KONG—Hoya Vision Care officially presented interim 6-month clinical evidence from a randomized controlled clinical trial evaluating the safety and efficacy of MiYOSMART iQ spectacle lenses in children aged 4-12 with progressive myopia at the 41st Asia-Pacific Academy of Ophthalmology Congress held here on February 6, the company announced. MiYOSMART iQ spectacle lenses are Hoya Vision Care’s novel myopia control solution that builds on its clinically proven Defocus Incorporated Multiple Segments (D.I.M.S.) technology. The MiYOSMART iQ spectacle lenses feature Triple Enhanced Design (DIMS TED).